Dasatinib

Generic Name: Dasatinib

Brand Names: Sprycel

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆ClN_₇O_₂S

CAS Number: 302962-49-8

Unique Ingredient Identifier: X78UG0A0RN

Background: Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication: Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Dasatinib
Drug: daunorubicin
Drug: Cytarabine

First Posted Date: 2009-02-25

Last Posted Date: 2016-03-01

Lead Sponsor: University of Ulm

Target Recruit Count: 89

Registration Number: NCT00850382

Locations: 🇦🇹
Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹
Elisabethinen Krankenhaus, Linz, Austria
🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria

and more 47 locations

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

Early Phase 1

Terminated

Conditions: Mucinous Adenocarcinoma of the Rectum
Stage IV Colon Cancer
Liver Metastases
Mucinous Adenocarcinoma of the Colon
Recurrent Colon Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IV Rectal Cancer

Interventions: Procedure: therapeutic conventional surgery
Biological: cetuximab
Drug: dasatinib
Other: laboratory biomarker analysis

First Posted Date: 2009-02-04

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT00835679

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Dasatinib
Drug: Erlotinib

First Posted Date: 2009-01-22

Last Posted Date: 2016-06-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00826449

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2009-01-06

Last Posted Date: 2012-08-31

Lead Sponsor: Baylor Breast Care Center

Target Recruit Count: 22

Registration Number: NCT00817531

Locations: 🇺🇸
Baylor College of Medicine, Lester and Sue Smith Breast Center, Houston, Texas, United States

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2009-01-01

Last Posted Date: 2012-07-17

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 5

Registration Number: NCT00816283

Locations: 🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

First Posted Date: 2008-11-18

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 97

Registration Number: NCT00792948

Locations: 🇺🇸
Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
🇺🇸
Lawrence Memorial Hospital, Lawrence, Kansas, United States
🇺🇸
Southwest Medical Center, Liberal, Kansas, United States

and more 154 locations

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

First Posted Date: 2008-11-10

Last Posted Date: 2023-07-14

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 7

Registration Number: NCT00788125

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2008-11-07

Last Posted Date: 2016-06-30

Lead Sponsor: Duke University

Target Recruit Count: 37

Registration Number: NCT00787267

Locations: 🇺🇸
Durham VA Medical Center, Durham, North Carolina, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Duke Raleigh, Raleigh, North Carolina, United States

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: AZD6244
Drug: Dasatinib

First Posted Date: 2008-10-28

Last Posted Date: 2020-09-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 97

Registration Number: NCT00780676

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Phase 2

Active, not recruiting

Conditions: Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2008-10-22

Last Posted Date: 2023-09-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 130

Registration Number: NCT00777036

Locations: 🇮🇹
Local Institution - 006, Monza, Italy
🇲🇽
Local Institution - 0050, Monterrey, Nuevo Leon, Mexico
🇷🇺
Local Institution - 0023, Moscow, Russian Federation

and more 106 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy